Pre-mRNA splicing-associated diseases and therapies

ABSTRACT Precursor mRNA (pre-mRNA) splicing is an essential step in human gene expression and is carried out by a large macromolecular machine called the spliceosome. Given the spliceosome's role in shaping the cellular transcriptome, it is not surprising that mutations in the splicing machinery can result in a range of human diseases and disorders (spliceosomopathies). This review serves as an introduction into the main features of the pre-mRNA splicing machinery in humans and how changes in the function of its components can lead to diseases ranging from blindness to cancers. Recently, several drugs have been developed that interact directly with this machinery to change splicing outcomes at either the single gene or transcriptome-scale. We discuss the mechanism of action of several drugs that perturb splicing in unique ways. Finally, we speculate on what the future may hold in the emerging area of spliceosomopathies and spliceosome-targeted treatments.

[1]  K. Nikolić,et al.  Reversible Control of RNA Splicing by Photoswitchable Small Molecules. , 2023, Journal of the American Chemical Society.

[2]  C. Dienemann,et al.  Structural basis of catalytic activation in human splicing , 2023, Nature.

[3]  Gregory A. Newby,et al.  Base editing rescue of spinal muscular atrophy in cells and in mice , 2023, Science.

[4]  Robert J. Weatheritt,et al.  Global detection of human variants and isoforms by deep proteome sequencing , 2023, Nature Biotechnology.

[5]  Sonya M. Hanson,et al.  splice sites by noncanonical base-pairing to U1 snRNA involving , 2022 .

[6]  Yue Huang,et al.  DHX15 is involved in SUGP1-mediated RNA missplicing by mutant SF3B1 in cancer , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Yongmei Xie,et al.  An overview of PROTACs: a promising drug discovery paradigm , 2022, Molecular biomedicine.

[8]  A. Burlingame,et al.  Targeted high throughput mutagenesis of the human spliceosome reveals its in vivo operating principles , 2022, bioRxiv.

[9]  C. Burge,et al.  Splicing quality control mediated by DHX15 and its G-patch activator, SUGP1 , 2022, bioRxiv.

[10]  J. Winkler,et al.  An alternative splicing modulator decreases mutant HTT and improves the molecular fingerprint in Huntington’s disease patient neurons , 2022, Nature Communications.

[11]  M. Kolář,et al.  Retinitis pigmentosa associated mutations in mouse Prpf8 cause misexpression of circRNAs and degeneration of cerebellar granule neurons , 2022, bioRxiv.

[12]  M. Donahue,et al.  Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS/AML , 2022, bioRxiv.

[13]  W. P. Galej,et al.  Structural studies of the spliceosome: Bridging the gaps , 2022, Current opinion in structural biology.

[14]  Jessica L. Childs-Disney,et al.  Targeting RNA structures with small molecules , 2022, Nature Reviews Drug Discovery.

[15]  S. Butcher,et al.  Identification of transient intermediates during spliceosome activation by single molecule fluorescence microscopy , 2022, bioRxiv.

[16]  O. Abdel-Wahab,et al.  Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells , 2022, Nature Biotechnology.

[17]  S. Peltz,et al.  Small molecule splicing modifiers with systemic HTT-lowering activity , 2021, Nature Communications.

[18]  F. Weis,et al.  Structural basis of branch site recognition by the human spliceosome , 2021, Science.

[19]  Margaret A. Goralski,et al.  Targeting the spliceosome through RBM39 degradation results in exceptional responses in high-risk neuroblastoma models , 2021, Science advances.

[20]  Hong Zhang,et al.  RNA-binding protein 39: a promising therapeutic target for cancer , 2021, Cell death discovery.

[21]  B. Davidson,et al.  Regulated control of gene therapies by drug-induced splicing , 2021, Nature.

[22]  J. Al-Aama,et al.  Pre-mRNA Processing Factors and Retinitis Pigmentosa: RNA Splicing and Beyond , 2021, Frontiers in Cell and Developmental Biology.

[23]  Arun K. Ghosh,et al.  Structural basis of intron selection by U2 snRNP in the presence of covalent inhibitors , 2021, Nature Communications.

[24]  H. Dvinge,et al.  Human spliceosomal snRNA sequence variants generate variant spliceosomes , 2021, RNA.

[25]  I. Flinn,et al.  Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms , 2021, Leukemia.

[26]  Daniel G. Anderson,et al.  mRNA therapeutics: beyond vaccine applications. , 2021, Trends in molecular medicine.

[27]  J. Wolchok,et al.  Pharmacologic modulation of RNA splicing enhances anti-tumor immunity , 2021, Cell.

[28]  Kathryn E. Hentges,et al.  The role of splicing factors in retinitis pigmentosa: links to cilia. , 2021, Biochemical Society transactions.

[29]  J. Diedrich,et al.  Coupling of spliceosome complexity to intron diversity , 2021, Current Biology.

[30]  H. Ratni,et al.  Risdiplam, the First Approved Small Molecule Splicing Modifier Drug as a Blueprint for Future Transformative Medicines. , 2021, ACS medicinal chemistry letters.

[31]  W. Newman,et al.  The Role of the U5 snRNP in Genetic Disorders and Cancer , 2021, Frontiers in Genetics.

[32]  Jitendra Kumar Meena,et al.  Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer , 2021, Cell.

[33]  J. Boultwood,et al.  SF3B1 mutant myelodysplastic syndrome: Recent advances. , 2020, Advances in biological regulation.

[34]  R. Zhao,et al.  DEAH-Box RNA Helicases in Pre-mRNA Splicing. , 2020, Trends in biochemical sciences.

[35]  N. Gehring,et al.  Anything but Ordinary - Emerging Splicing Mechanisms in Eukaryotic Gene Regulation. , 2020, Trends in genetics : TIG.

[36]  G. Carvill,et al.  Poison exons in neurodevelopment and disease. , 2020, Current opinion in genetics & development.

[37]  J. Saint-Jeannet,et al.  Spliceosomopathies: Diseases and mechanisms , 2020, Developmental dynamics : an official publication of the American Association of Anatomists.

[38]  H. Stark,et al.  Molecular architecture of the human 17S U2 snRNP , 2020, Nature.

[39]  K. Horie-Inoue,et al.  Roles of Splicing Factors in Hormone-Related Cancer Progression , 2020, International journal of molecular sciences.

[40]  V. Hornak,et al.  Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex , 2019, Nature Chemical Biology.

[41]  Paul M Wehn,et al.  Structural Basis and Kinetic Pathway of RBM39 Recruitment to DCAF15 by a Sulfonamide Molecular Glue E7820. , 2019, Structure.

[42]  A. Grossfield,et al.  Structures of SF3b1 reveal a dynamic Achilles heel of spliceosome assembly: Implications for cancer-associated abnormalities and drug discovery. , 2019, Biochimica et biophysica acta. Gene regulatory mechanisms.

[43]  H. Stark,et al.  Structural Insights into Nuclear pre-mRNA Splicing in Higher Eukaryotes. , 2019, Cold Spring Harbor perspectives in biology.

[44]  John A. Calarco,et al.  Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma , 2019, Nature.

[45]  Anna Knörlein,et al.  Structural basis of a small molecule targeting RNA for a specific splicing correction , 2019, Nature Chemical Biology.

[46]  R. Rabadán,et al.  Disease-Causing Mutations in SF3B1 Alter Splicing by Disrupting Interaction with SUGP1. , 2019, Molecular cell.

[47]  Julio Delgado,et al.  The U1 spliceosomal RNA is recurrently mutated in multiple cancers , 2019, Nature.

[48]  M. Carmo-Fonseca,et al.  Targeting mRNA processing as an anticancer strategy , 2019, Nature Reviews Drug Discovery.

[49]  Alexander V Penson,et al.  Spliceosomal disruption of the non-canonical BAF complex in cancer , 2019, Nature.

[50]  A. Hoskins,et al.  Structural and functional modularity of the U2 snRNP in pre-mRNA splicing , 2019, Critical reviews in biochemistry and molecular biology.

[51]  Rhiju Das,et al.  A unified mechanism for intron and exon definition and back-splicing , 2019, Nature.

[52]  N. Gray,et al.  Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15 , 2019, bioRxiv.

[53]  A. Krainer,et al.  Antisense Oligonucleotide Therapies for Neurodegenerative Diseases. , 2019, Annual review of neuroscience.

[54]  L. Maquat,et al.  Quality and quantity control of gene expression by nonsense-mediated mRNA decay , 2019, Nature Reviews Molecular Cell Biology.

[55]  A. Hoskins,et al.  Chemical Inhibition of Pre-mRNA Splicing in Living Saccharomyces cerevisiae. , 2019, Cell chemical biology.

[56]  A. Krainer,et al.  Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia. , 2019, Cancer cell.

[57]  K. Nagai,et al.  Structural Basis of Nuclear pre-mRNA Splicing: Lessons from Yeast. , 2019, Cold Spring Harbor perspectives in biology.

[58]  Dahui Qin.  Next-generation sequencing and its clinical application , 2019, Cancer biology & medicine.

[59]  Angela N. Brooks,et al.  Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. , 2018, JCI insight.

[60]  B. Ebert,et al.  Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations. , 2018, Cancer cell.

[61]  Michael Reutlinger,et al.  Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA). , 2018, Journal of medicinal chemistry.

[62]  Joerg E Braun,et al.  Synergistic assembly of human pre-spliceosomes across introns and exons , 2018, eLife.

[63]  H. Dvinge,et al.  RNA components of the spliceosome regulate tissue- and cancer-specific alternative splicing , 2018, bioRxiv.

[64]  A. Hoskins,et al.  Functional analysis of Hsh155/SF3b1 interactions with the U2 snRNA/branch site duplex , 2018, RNA.

[65]  Abramowicz Anna,et al.  Splicing mutations in human genetic disorders: examples, detection, and confirmation , 2018, Journal of Applied Genetics.

[66]  C. Will,et al.  Structural Basis of Splicing Modulation by Antitumor Macrolide Compounds. , 2018, Molecular cell.

[67]  Ping Zhu,et al.  Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. , 2018, Cell reports.

[68]  M. Warmuth,et al.  H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers , 2018, Nature Medicine.

[69]  Peter G. Smith,et al.  Targeting splicing abnormalities in cancer. , 2018, Current opinion in genetics & development.

[70]  Qiang Zhou,et al.  The cryo-EM structure of the SF3b spliceosome complex bound to a splicing modulator reveals a pre-mRNA substrate competitive mechanism of action , 2018, Genes & development.

[71]  S. Butcher,et al.  The life of U6 small nuclear RNA, from cradle to grave , 2018, RNA.

[72]  J. Valcárcel,et al.  Molecular basis of differential 3′ splice site sensitivity to anti-tumor drugs targeting U2 snRNP , 2017, Nature Communications.

[73]  Adrian R. Krainer,et al.  Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers , 2017, Nature Communications.

[74]  R. J. Ramamurthi,et al.  Nusinersen versus Sham Control in Infantile‐Onset Spinal Muscular Atrophy , 2017, The New England journal of medicine.

[75]  M. Warmuth,et al.  Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A–SF3b complex , 2017, Nature Communications.

[76]  Margaret A. Goralski,et al.  Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15 , 2017, Science.

[77]  T. Owa,et al.  Selective degradation of splicing factor CAPERα by anticancer sulfonamides. , 2017, Nature chemical biology.

[78]  Kamil J. Cygan,et al.  Pathogenic variants that alter protein code often disrupt splicing , 2017, Nature Genetics.

[79]  M. Jurica,et al.  Modulating splicing with small molecular inhibitors of the spliceosome , 2017, Wiley interdisciplinary reviews. RNA.

[80]  F. Slack,et al.  MicroRNA therapeutics: towards a new era for the management of cancer and other diseases , 2017, Nature Reviews Drug Discovery.

[81]  J. Karanicolas,et al.  Musashi RNA-Binding Proteins as Cancer Drivers and Novel Therapeutic Targets , 2017, Clinical Cancer Research.

[82]  A. Hoskins,et al.  SF3b1 mutations associated with myelodysplastic syndromes alter the fidelity of branchsite selection in yeast , 2017, Nucleic acids research.

[83]  Susana Rodríguez-Santiago,et al.  SF3B1/Hsh155 HEAT motif mutations affect interaction with the spliceosomal ATPase Prp5, resulting in altered branch site selectivity in pre-mRNA splicing , 2016, Genes & development.

[84]  Eunhee Kim,et al.  RNA splicing factors as oncoproteins and tumour suppressors , 2016, Nature Reviews Cancer.

[85]  M. Moore,et al.  Single molecule analysis reveals reversible and irreversible steps during spliceosome activation , 2016, eLife.

[86]  C. Guthrie,et al.  Prp8 retinitis pigmentosa mutants cause defects in the transition between the catalytic steps of splicing , 2016, RNA.

[87]  A. Godzik,et al.  UHM-ULM interactions in the RBM39-U2AF65 splicing-factor complex. , 2016, Acta crystallographica. Section D, Structural biology.

[88]  Arun K. Ghosh,et al.  Interchangeable SF3B1 inhibitors interfere with pre-mRNA splicing at multiple stages , 2016, RNA.

[89]  M. Swanson,et al.  RNA mis-splicing in disease , 2015, Nature Reviews Genetics.

[90]  M. Warmuth,et al.  Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point. , 2015, Cell reports.

[91]  A. Krainer,et al.  The spliceosome, a potential Achilles heel of MYC-driven tumors , 2015, Genome Medicine.

[92]  C. Soneson,et al.  Human Mpn1 promotes post‐transcriptional processing and stability of U6atac , 2015, FEBS letters.

[93]  Thomas M. Smith,et al.  SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice. , 2015, Nature chemical biology.

[94]  P. Patil,et al.  Incomplete splicing of neutrophil-specific genes affects neutrophil development in a zebrafish model of poikiloderma with neutropenia , 2015, RNA biology.

[95]  T. Misteli,et al.  Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing , 2015, Nature Communications.

[96]  Dennis Carson,et al.  Transcriptome Sequencing Reveals Potential Mechanism of Cryptic 3’ Splice Site Selection in SF3B1-mutated Cancers , 2015, PLoS Comput. Biol..

[97]  R. Ferris,et al.  Regulation of HPV16 E6 and MCL1 by SF3B1 inhibitor in head and neck cancer cells , 2014, Scientific Reports.

[98]  Anirvan Ghosh,et al.  SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy , 2014, Science.

[99]  C. J. O’Donnell,et al.  Spliceostatin hemiketal biosynthesis in Burkholderia spp. is catalyzed by an iron/α-ketoglutarate–dependent dioxygenase , 2014, Proceedings of the National Academy of Sciences.

[100]  R. Padgett,et al.  Biochemical defects in minor spliceosome function in the developmental disorder MOPD I , 2014, RNA.

[101]  Paul K. Korir,et al.  A mutation in a splicing factor that causes retinitis pigmentosa has a transcriptome-wide effect on mRNA splicing , 2014, BMC Research Notes.

[102]  Michael R. Green,et al.  Cancer-relevant Splicing Factor CAPERα Engages the Essential Splicing Factor SF3b155 in a Specific Ternary Complex* , 2014, The Journal of Biological Chemistry.

[103]  S. Daiger,et al.  Genes and mutations causing retinitis pigmentosa , 2013, Clinical genetics.

[104]  C. Will,et al.  Inhibition of RNA Helicase Brr2 by the C-Terminal Tail of the Spliceosomal Protein Prp8 , 2013, Science.

[105]  C. Azzalin,et al.  The Mpn1 RNA exonuclease: Cellular functions and implication in disease , 2013, FEBS letters.

[106]  Yang Gao,et al.  Chemical perturbation of Mcl-1 pre-mRNA splicing to induce apoptosis in cancer cells. , 2013, ACS chemical biology.

[107]  P. Campbell,et al.  Aberrant 3' oligoadenylation of spliceosomal U6 small nuclear RNA in poikiloderma with neutropenia. , 2013, Blood.

[108]  C. Soneson,et al.  Mpn1, mutated in poikiloderma with neutropenia protein 1, is a conserved 3'-to-5' RNA exonuclease processing U6 small nuclear RNA. , 2012, Cell reports.

[109]  M. Frilander,et al.  The significant other: splicing by the minor spliceosome , 2012, Wiley interdisciplinary reviews. RNA.

[110]  K. Ginalski,et al.  C16orf57, a gene mutated in poikiloderma with neutropenia, encodes a putative phosphodiesterase responsible for the U6 snRNA 3' end modification. , 2012, Genes & development.

[111]  T. Cooper,et al.  Pre-mRNA splicing in disease and therapeutics. , 2012, Trends in molecular medicine.

[112]  A. Krainer,et al.  Widespread recognition of 5' splice sites by noncanonical base-pairing to U1 snRNA involving bulged nucleotides. , 2012, Genes & development.

[113]  H. Scott,et al.  Spliceosome mutations in hematopoietic malignancies , 2011, Nature Genetics.

[114]  E. Giné,et al.  Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia , 2011, Nature Genetics.

[115]  Scott L. Pomeroy,et al.  Molecular subgroups of medulloblastoma: the current consensus , 2011, Acta Neuropathologica.

[116]  S. Sugano,et al.  Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.

[117]  D. Staněk,et al.  Where splicing joins chromatin , 2011, Nucleus.

[118]  Sandya Liyanarachchi,et al.  Mutations in U4atac snRNA, a Component of the Minor Spliceosome, in the Developmental Disorder MOPD I , 2011, Science.

[119]  M. Moore,et al.  Ordered and Dynamic Assembly of Single Spliceosomes , 2011, Science.

[120]  Miaosheng Li,et al.  Structural requirements for the antiproliferative activity of pre-mRNA splicing inhibitor FR901464. , 2011, Chemistry.

[121]  S. Horinouchi,et al.  Identification of SAP155 as the target of GEX1A (Herboxidiene), an antitumor natural product. , 2011, ACS chemical biology.

[122]  R. O’Keefe,et al.  The function of the NineTeen Complex (NTC) in regulating spliceosome conformations and fidelity during pre-mRNA splicing. , 2010, Biochemical Society transactions.

[123]  M. Estelle,et al.  Auxin perception--structural insights. , 2010, Cold Spring Harbor perspectives in biology.

[124]  Steven L Salzberg,et al.  Between a chicken and a grape: estimating the number of human genes , 2010, Genome Biology.

[125]  C. Guthrie,et al.  Conformational dynamics of single pre-mRNA molecules during in vitro splicing , 2010, Nature Structural &Molecular Biology.

[126]  Fabio Macciardi,et al.  Targeted next-generation sequencing appoints c16orf57 as clericuzio-type poikiloderma with neutropenia gene. , 2010, American journal of human genetics.

[127]  T. Nilsen,et al.  Expansion of the eukaryotic proteome by alternative splicing , 2010, Nature.

[128]  Henning Urlaub,et al.  The evolutionarily conserved core design of the catalytic activation step of the yeast spliceosome. , 2009, Molecular cell.

[129]  Jason M. Edmonds,et al.  Tetracyclines That Promote SMN2 Exon 7 Splicing as Therapeutics for Spinal Muscular Atrophy , 2009, Science Translational Medicine.

[130]  C. Will,et al.  The Spliceosome: Design Principles of a Dynamic RNP Machine , 2009, Cell.

[131]  C. Guthrie,et al.  ATP-dependent unwinding of U4/U6 snRNAs by the Brr2 helicase requires the C-terminus of Prp8 , 2008, Nature Structural &Molecular Biology.

[132]  Eric T. Wang,et al.  Alternative Isoform Regulation in Human Tissue Transcriptomes , 2008, Nature.

[133]  Soo-Chen Cheng,et al.  Both Catalytic Steps of Nuclear Pre-mRNA Splicing Are Reversible , 2008, Science.

[134]  J. Beggs,et al.  prp8 mutations that cause human retinitis pigmentosa lead to a U5 snRNP maturation defect in yeast , 2007, Nature Structural &Molecular Biology.

[135]  M. Hagiwara,et al.  Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA , 2007, Nature Chemical Biology.

[136]  T. Owa,et al.  Splicing factor SF3b as a target of the antitumor natural product pladienolide , 2007, Nature Chemical Biology.

[137]  A. Kornblihtt,et al.  The connection between splicing and cancer , 2006, Journal of Cell Science.

[138]  P. Francis.  Genetics of Inherited Retinal Disease , 2006 .

[139]  F. Clark,et al.  Understanding alternative splicing: towards a cellular code , 2005, Nature Reviews Molecular Cell Biology.

[140]  J. Beggs,et al.  Prp8 protein: at the heart of the spliceosome. , 2005, RNA.

[141]  B. O’Malley,et al.  Steroid Hormone Receptor Coactivation and Alternative RNA Splicing by U2AF65-Related Proteins CAPERα and CAPERβ , 2005 .

[142]  T. Yamori,et al.  Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. III. In vitro and in vivo antitumor activities. , 2004, The Journal of antibiotics.

[143]  S. Horinouchi,et al.  GEX1 compounds, novel antitumor antibiotics related to herboxidiene, produced by Streptomyces sp. II. The effects on cell cycle progression and gene expression. , 2002, The Journal of antibiotics.

[144]  D. Krause,et al.  Alternative first exons of PTCH1 are differentially regulated in vivo and may confer different functions to the PTCH1 protein , 2002, Oncogene.

[145]  A. Krainer,et al.  Listening to silence and understanding nonsense: exonic mutations that affect splicing , 2002, Nature Reviews Genetics.

[146]  T. Kitahara,et al.  A synthesis of FR901464 , 2001 .

[147]  D. Hunt,et al.  A human homolog of yeast pre-mRNA splicing gene, PRP31, underlies autosomal dominant retinitis pigmentosa on chromosome 19q13.4 (RP11). , 2001, Molecular cell.

[148]  D. Mackey,et al.  Mutations in the pre-mRNA splicing factor gene PRPC8 in autosomal dominant retinitis pigmentosa (RP13). , 2001, Human molecular genetics.

[149]  R. Deshaies,et al.  Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[150]  M. Nakafuku,et al.  Regulation of Gli2 and Gli3 activities by an amino-terminal repression domain: implication of Gli2 and Gli3 as primary mediators of Shh signaling. , 1999, Development.

[151]  T. Owa,et al.  Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. , 1999, Journal of medicinal chemistry.

[152]  C. Guthrie,et al.  Mechanical Devices of the Spliceosome: Motors, Clocks, Springs, and Things , 1998, Cell.

[153]  M. Okuhara,et al.  New antitumor substances, FR901463, FR901464 and FR901465. II. Activities against experimental tumors in mice and mechanism of action. , 1996, The Journal of antibiotics.

[154]  P. Sharp,et al.  Evidence for two active sites in the spliceosome provided by stereochemistry of pre-mRNA splicing , 1993, Nature.

[155]  D. Mccormick.  Sequence the Human Genome , 1986, Bio/Technology.

[156]  James P. Orengo,et al.  Alternative splicing in disease. , 2007, Advances in experimental medicine and biology.

[157]  D. Brow,et al.  Allosteric cascade of spliceosome activation. , 2002, Annual review of genetics.

[158]  S. Berget,et al.  Exon definition may facilitate splice site selection in RNAs with multiple exons. , 1990, Molecular and cellular biology.